Wall Street Zen Upgrades Revelation Biosciences (NASDAQ:REVB) to “Sell”

Revelation Biosciences (NASDAQ:REVB) was upgraded by equities researchers at Wall Street Zen to a “sell” rating in a research note issued on Friday.

Revelation Biosciences Stock Down 7.4%

REVB opened at $0.76 on Friday. The stock has a fifty day moving average of $1.97 and a 200-day moving average of $3.69. The firm has a market capitalization of $728,640.00, a P/E ratio of -0.01 and a beta of -0.09. Revelation Biosciences has a 12-month low of $0.74 and a 12-month high of $56.00.

Revelation Biosciences (NASDAQ:REVB) last released its earnings results on Thursday, May 8th. The company reported ($2.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($6.88) by $4.77. On average, analysts expect that Revelation Biosciences will post -49.33 earnings per share for the current fiscal year.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.